Skip to content

13F-HR filed by HARVARD MANAGEMENT CO INC

HARVARD MANAGEMENT CO INC filed this 13F-HR for the quarter ended 2020-12-31, filed 2021-02-12, with 30 holding rows worth $1,843,661,000.

Accession
0000950123-21-001978
Filed
2021-02-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2020

A holdings report, 30 entries on the cover page, a total value of $1,843,661,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,843,659,000 with VALUE read as thousands by filing date, 13F file number 028-03879. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ROYALTY PHARMA PLCG7709Q104SHS CLASS A14,690,780$735,274,000thousands by filing date
Salesforce.com, Inc79466L302COM927,541$206,406,000thousands by filing date
Microsoft Corp594918104COM821,062$182,621,000thousands by filing date
ABCELLERA BIOLOGICS INC COM00288U106Stock4,105,095$165,189,000thousands by filing date
LIGHT & WONDER INC COM80874P109Stock2,678,571$111,134,000thousands by filing date
META PLATFORMS INC CL A30303M102COM406,540$111,050,000thousands by filing date
PALO ALTO NETWORKS INC697435105COM167,202$59,422,000thousands by filing date
PRAXIS PRECISION MEDICINES I74006W108COM792,617$43,610,000thousands by filing date
INVESCO QQQ TR46090E103COM112,765$35,379,000thousands by filing date
REVOLUTION MEDICINES INC COM76155X100Stock670,382$26,540,000thousands by filing date
ISHARES TR CORE S&P 500 ETF464287200SHS64,672$24,277,000thousands by filing date
RELAY THERAPEUTICS INC COM75943R102Stock541,124$22,489,000thousands by filing date
KINNATE BIOPHARMA INC49705R105COM498,001$19,810,000thousands by filing date
SPDR GOLD TR78463V107GOLD SHS96,619$17,233,000thousands by filing date
GENERATION BIO CO37148K100COM521,460$14,783,000thousands by filing date
PLIANT THERAPEUTICS INC729139105COM562,379$12,777,000thousands by filing date
NURIX THERAPEUTICS INC67080M103COMMON STOCK314,762$10,349,000thousands by filing date
Vanguard FTSE Developed Markets ETF921943858SHS174,041$8,216,000thousands by filing date
NUCANA PLC67022C106ADR1,678,239$7,535,000thousands by filing date
FULCRUM THERAPEUTICS INC359616109COMMON STOCK410,714$4,809,000thousands by filing date
iShares Core S&P Small-Cap ETF464287804SHS49,710$4,568,000thousands by filing date
VWO922042858SHS80,360$4,027,000thousands by filing date
IJH464287507COM16,255$3,736,000thousands by filing date
SERES THERAPEUTICS INC81750R102COM131,847$3,230,000thousands by filing date
FS DEV CORP303020101COM CL A250,000$2,750,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock332,610$2,608,000thousands by filing date
DYNE THERAPEUTICS INC COM26818M108Stock107,252$2,252,000thousands by filing date
CARLYLE GROUP INC COM14316J108Stock23,600$742,000thousands by filing date
TWILIO INC CL A90138F102Stock2,021$684,000thousands by filing date
PROGYNY INC COM74340E103Stock3,755$159,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-21-001978this filing2021-02-12acceptance time not in the bulk data set